Earnings Feed
Start Free
Aclaris Therapeutics, Inc.·4

Jun 8, 4:15 PM ET

SCHIFF ANDREW N 4

4 · Aclaris Therapeutics, Inc. · Filed Jun 8, 2026

Research Summary

AI-generated summary of this filing

Updated

Aclaris (ACRS) Director Andrew Schiff Receives RSUs, Exercises 11,580

What Happened

  • Andrew N. Schiff, a director of Aclaris Therapeutics (ACRS), received equity awards and completed a same‑day conversion/disposition of derivative securities. On June 4, 2026 he was granted two awards totaling 53,337 restricted stock units (42,350 + 10,987) at $0.00. On June 5, 2026 the filing shows an exercise/conversion of 11,580 derivative shares (acquired) and an immediate disposition of 11,580 shares (reported proceeds $0.00).
  • These were awards/derivative transactions (not open‑market purchases or sales for cash). Awards were granted at no cash price; the reported $0 disposition proceeds mean the filing does not show cash proceeds from the same‑day disposition.

Key Details

  • Transaction dates and reported prices:
    • 2026-06-04: Grant/award of 42,350 RSUs and 10,987 RSUs, $0.00 per unit (total = 53,337 RSUs).
    • 2026-06-05: Exercise/conversion of 11,580 derivative shares (acquired; price N/A) and same‑day disposition of 11,580 shares (reported proceeds $0.00).
  • Shares owned after the transactions: Not specified in the provided filing.
  • Notable footnotes from the filing:
    • F1: Each RSU represents a contingent right to one share of common stock.
    • F6: The shares underlying these RSUs vested on June 5, 2026.
    • F4/F5: Grants were made under the director compensation policy/issuer plan; some awards vest according to plan schedules.
    • F2: Some reportable securities are held by Aisling Capital entities; Dr. Schiff disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
  • Filing timeliness: The report was filed June 8, 2026 for transactions on June 4–5; the filing does not indicate a late filing status.

Context

  • RSUs are awards (not purchases) and only become shares if/when they vest; the filing confirms vesting occurred June 5 for the RSUs referenced.
  • The same‑day conversion followed by a $0 reported disposition is commonly associated with share settlement or withholding arrangements (the filing does not explain the reason), so this is not presented as an open‑market sale for cash.
  • The filing includes institutional/partnership ownership details (Aisling entities) and a disclaimer by Dr. Schiff about beneficial ownership of those holdings.

Insider Transaction Report

Form 4
Period: 2026-06-04
Aclaris Therapeutics, Inc.ACRS
SCHIFF ANDREW N
Director
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-05+11,580→ 25,540 total
  • Award

    Stock Option (Right to Buy)

    [F3][F4]
    2026-06-04+42,350→ 42,350 total
    Exercise: $4.71Exp: 2036-06-03→ Common Stock (42,350 underlying)
  • Award

    Restricted Stock Units

    [F1][F5][F4]
    2026-06-04+10,987→ 10,987 total
    → Common Stock (10,987 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F6]
    2026-06-05−11,580→ 0 total
    → Common Stock (11,580 underlying)
Holdings

  • Common Stock

    [F2]
    (indirect: By Aisling Capital IV LP)
    434,455
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
  • [F3]The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
  • [F4]This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
  • [F5]The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
  • [F6]The shares underlying these restricted stock units vested on June 5, 2026.
Signature
/s/ Matthew Rothman, Attorney-in-Fact|2026-06-08

Documents

1 file
  • 4
    form4-06082026_040612.xmlPrimary